Cargando…

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint

Detalles Bibliográficos
Autores principales:	Kubica, Jacek, Adamski, Piotr, Gajda, Robert, Gąsior, Mariusz, Gierlotka, Marek, Gil, Robert, Jaguszewski, Miłosz, Kubica, Aldona, Kuliczkowski, Wiktor, Kurek, Krzysztof, Ładny, Jerzy Robert, Michalski, Piotr, Navarese, Eliano Pio, Niezgoda, Piotr, Ostrowska, Małgorzata, Tycińska, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2023
Materias:	Clinical Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508081/ https://www.ncbi.nlm.nih.gov/pubmed/37401419 http://dx.doi.org/10.5603/CJ.a2023.0043

Ejemplares similares

Pretreatment with P2Y(12) Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported?
por: Niezgoda, Piotr, et al.
Publicado: (2023)

Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
por: Niezgoda, Piotr, et al.
Publicado: (2022)

ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial
por: Kubica, Aldona, et al.
Publicado: (2021)

IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
por: Kubica, Jacek, et al.
Publicado: (2022)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2019)

Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
por: Kubica, Jacek, et al.
Publicado: (2022)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
por: Kubica, Jacek, et al.
Publicado: (2023)

Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
por: Kubica, Jacek, et al.
Publicado: (2022)

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The RECOVERY-SIRIO randomized trial
por: Navarese, Eliano P., et al.
Publicado: (2022)

Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
por: Kubica, Jacek, et al.
Publicado: (2016)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Tubek, Stanisław, et al.
Publicado: (2021)

Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study
por: Kubica, Jacek, et al.
Publicado: (2021)

Genetic determinants of platelet response to clopidogrel
por: Kubica, Aldona, et al.
Publicado: (2011)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

ISAR-REACT 5 — What have we learned?
por: Kubica, Jacek, et al.
Publicado: (2019)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction
por: Swiatkiewicz, Iwona, et al.
Publicado: (2012)

Therapy Discontinuation after Myocardial Infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

Determinants of Lipid Parameters in Patients without Diagnosed Cardiovascular Disease—Results of the Polish Arm of the EUROASPIRE V Survey
por: Ratajczak, Jakub, et al.
Publicado: (2023)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Effects of Multidisciplinary Rehabilitation Program in Patients with Long COVID-19: Post-COVID-19 Rehabilitation (PCR SIRIO 8) Study
por: Ostrowska, Małgorzata, et al.
Publicado: (2023)

Comparison of reorganized versus unaltered cardiology departments during the COVID-19 era: A subanalysis of the COV-HF-SIRIO 6 study
por: Ostrowska, Małgorzata, et al.
Publicado: (2022)

The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction
por: Kosobucka, Agata, et al.
Publicado: (2022)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Impact of COVID‐19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV‐HF‐SIRIO 6 study)
por: Kubica, Jacek, et al.
Publicado: (2021)

Case report: First treatment of acute ischaemic stroke in a patient on active rivaroxaban therapy using andexanet alfa and rtPA combined with early complete recovery
por: Karaszewski, Bartosz, et al.
Publicado: (2023)

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial
por: Kubica, Jacek, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u74uplvvhr6dnor1io07sgvsnn